各種癌での癌免疫療法の実際

参考文献

胃癌
1. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue
H, Takesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with MAGE peptide is a novel
therapeutic approach for gastrointestinal carcinomas.
Clin Cancer Res. 2001 Aug;7(8):2277-84.
2.

Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y. Dendritic cells
pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients withgastric cancer. Clin Cancer Res. 2002 Nov;8(11):3394-400.

3. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y.
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patientswith advanced gastric cancer: a randomized trial.
Clin Cancer Res. 2002 Jun;8(6):1767-71.
大腸癌
1. Hoover, H. C., Jr., Surdyke, M. G., Dangel, R. B., Peters, L. C., and Hanna, M. G., Jr. Prospectively
randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer,

55: 1236-1243, 1985.
2. Gray, B. N., Walker, C., Andrewartha, L., Freeman, S., and Bennett, R. C. Controlled clinical trial ofadjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large
bowel cancer. J Surg Oncol, 40: 34-37, 1989.
3. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W.,
and Schirrmacher, V. Active specific immunotherapy with Newcastle-disease-virus-modified
autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluationof clinical response of a phase II-trial. Cancer Immunol Immunother, 35: 325-330, 1992.
4. Hoover, H. C., Jr., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J.,
Muenz, L. R., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for human colorectal
cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol, 11:390-399, 1993.
5. Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J.,
Meijer, C. J., Bloemena, E., Ransom, J. H., Hanna, M. G., Jr., and Pinedo, H. M. Active specificimmunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353:
345-350, 1999.
6. Harris, J. E., Ryan, L., Hoover, H. C., Jr., Stuart, R. K., Oken, M. M., Benson, A. B., 3rd, Mansour,E., Haller, D. G., Manola, J., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy forstage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology
Group Study E5283. J Clin Oncol, 18: 148-157, 2000.
MF Shinjuku Bldg. 5-6-12 Shinjuku Shinjuku-ku Tokyo 〒160-0022 Phone:+81(0)3 5919 1762 Fax:+81(0)3 5919 1702
Copyright(C);2011 Bio-Thera Clinic All rights Reserved.

7. Rains, N., Cannan, R. J., Chen, W., and Stubbs, R. S. Development of a dendritic cell (DC)-based
vaccine for patients with advanced colorectal cancer. Hepatogastroenterology, 48: 347-351, 2001.
8. Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski, D., Proia,A., Neidzwiecki, D., Clavien, P. A., Hurwitz, H. I., Schlom, J., Gilboa, E., and Lyerly, H. K.
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen
mRNA. Cancer Invest, 21: 341-349, 2003.
9. Liu, K. J., Wang, C. C., Chen, L. T., Cheng, A. L., Lin, D. T., Wu, Y. C., Yu, W. L., Hung, Y. M., Yang,H. Y., Juang, S. H., and Whang-Peng, J. Generation of carcinoembryonic antigen (CEA)-specificT-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients aftervaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res, 10: 2645-2651, 2004.
10. Sato, Y., Maeda, Y., Shomura, H., Sasatomi, T., Takahashi, M., Une, Y., Kondo, M., Shinohara, T.,Hida, N., Katagiri, K., Sato, K., Sato, M., Yamada, A., Yamana, H., Harada, M., Itoh, K., and Todo, S.
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal
carcinoma patients. Br J Cancer, 90: 1334-1342, 2004.
11. Dillman, R. O., Soori, G., DePriest, C., Nayak, S. K., Beutel, L. D., Schiltz, P. M., de Leon, C., andO'Connor, A. A. Treatment of human solid malignancies with autologous activated lymphocytes andcimetidine: a phase II trial of the cancer biotherapy research group. Cancer Biother Radiopharm,

18: 727-733, 2003.
12. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A.
Harstrick, E. Van Cutsem. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) inpatients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic
colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22: page 252, 2003 (abstr 1012)
肺癌
1.

Kimura H, Yamaguchi Y.

A phase III randomized study of interleukin-2 lymphokine-activatedkiller cell immunotherapy combined with chemotherapy or radiotherapy after curative or
noncurative resection of primary lung carcinoma.
Cancer. 1997 Jul 1;80(1):42-9.
2.

Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa
K, Fujino S. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.Int J Mol Med.
2003 Oct;12(4):493-502.

3.

Nemunaitis J. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lungcancer. J Control Release. 2003 Aug 28;91(1-2):225-31.

MF Shinjuku Bldg. 5-6-12 Shinjuku Shinjuku-ku Tokyo 〒160-0022 Phone:+81(0)3 5919 1762 Fax:+81(0)3 5919 1702
Copyright(C);2011 Bio-Thera Clinic All rights Reserved.

乳癌1.

Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa
K, Fujino S. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.

Int J Mol

Med. 2003 Oct;12(4):493-502.
2.

Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T,
Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D. Fusion cellvaccination of patients with metastatic breast and renal cancer induces immunological andclinical responses. Clin Cancer Res. 2004 Jul 15;10(14):4699-708.

3.

Miles D, Papazisis K. Rationale for the Clinical Development of STn-KLH (Theratope(R)) andAnti-MUC-1

Vaccines in Breast Cancer. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8.

原発性肝臓癌（肝細胞癌）
1.

Ichida, T., Higuchi, K., Arakawa, K., Ohta, H., Sugiyama, K., Miyagiwa, M., Nohzawa, A., Satoh, T.,
Sasaki, H., and Ichida, F. Treatment of hepatocellular carcinoma utilizing lymphokine-activatedkiller cells and interleukin-2. Cancer Chemother Pharmacol, 23 Suppl: S45-48, 1989.

2.

Onishi, S., Saibara, T., Fujikawa, M., Sakaeda, H., Matsuura, Y., Matsunaga, Y., and Yamamoto, Y.
Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 inpatients with unresectable hepatocellular carcinoma. Hepatology, 10: 349-353, 1989.

3.

Yeung, A. W., Pang, Y. K., Tsang, Y. C., Wong, S. W., and Leung, J. S. Short-duration in vitro
interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study
trial. Cancer, 71: 3633-3639, 1993.

4.

Haruta, I., Yamauchi, K., Aruga, A., Komatsu, T., Takasaki, K., Hayashi, N., and Hanyu, F.
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced
hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J ImmunotherEmphasis Tumor Immunol, 19: 218-223, 1996.

5.

Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K.,
Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T. Adoptive immunotherapy to lower
postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 356: 802-807,2000.

6.

Iwashita, Y., Tahara, K., Goto, S., Sasaki, A., Kai, S., Seike, M., Chen, C. L., Kawano, K., andKitano, S. A phase I study of autologous dendritic cell-based immunotherapy for patients withunresectable primary liver cancer. Cancer Immunol Immunother, 52: 155-161, 2003.8.

7.

Peng, B. G., Liu, S. Q., Kuang, M., He, Q., Totsuka, S., Huang, L., Huang, J., Lu, M. D., Liang, L. J.,
Leong, K. W., and Ohno, T. Autologous fixed tumor vaccine: a formulation withcytokine-microparticles for protective immunity against recurrence of human hepatocellular
carcinoma. Jpn J Cancer Res, 93: 363-368, 2002.

MF Shinjuku Bldg. 5-6-12 Shinjuku Shinjuku-ku Tokyo 〒160-0022 Phone:+81(0)3 5919 1762 Fax:+81(0)3 5919 1702
Copyright(C);2011 Bio-Thera Clinic All rights Reserved.

8.

Ladhams, A., Schmidt, C., Sing, G., Butterworth, L., Fielding, G., Tesar, P., Strong, R., Leggett, B.,
Powell, L., Maddern, G., Ellem, K., and Cooksley, G. Treatment of non-resectable hepatocellularcarcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol, 17: 889-896,2002.

9.

Kuang, M., Peng, B. G., Lu, M. D., Liang, L. J., Huang, J. F., He, Q., Hua, Y. P., Totsuka, S., Liu, S.
Q., Leong, K. W., and Ohno, T. Phase II randomized trial of autologous formalin-fixed tumor
vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res, 10: 1574-1579,
2004.

膵臓癌
1.

有賀チン。

淳、谷川啓司、清水公一、羽鳥2.

隆、須藤俊美、高崎健。MUC1 ペプチドを用いたがんワク

血液・腫瘍科, 45(1), 28-35, 2002

Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin
peptide vaccine.

Induction of specific immune reactivity in patients with adenocarcinoma. JSurg Res. 1996 Jun; 63(1): 298-304.
3.

Thomas Am, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins
M, Hruban RH, Jaffee EM.

Mesothelin-specfic CD8(+) T cell responses provide evidence of in vivo

cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

J Exp Med.

2004 Aug 2;200(3):297-306.

腎臓癌
1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, A progress report on thetreatment of 157 patients with advanced cancer using lymphokine-activated killer cells andinterleukin-2 or high dose interleukin-2 alone. N Engl j Med 1987, 316:889-95.
2. Pizza G, Vinci CD, Conte GL, Maver P, Dragoni E, Aiello E, Fornarola V, Bergami T, Busutti L,Boriani S, Palareti A, Capanna R.

immunotherapy of metastatic kidney cancer.

3. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S.

Adoptive

immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 andInterleukin-2.

1997 Feb 2;15:796-807.

4. Zou X, Jun do Y, Thomas AM, Huang X, Huang LQ, Mautner J. Mo W, Robbins PF, Pardoll DM,Jaffee EM.

Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treatedwith an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal
tumor cell vaccine.

Cancer Res. 2005 Feb 1;65(3):1079-88.

5. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW.

A phase I trial of

CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic
renal cell carcinoma.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3562-70.

MF Shinjuku Bldg. 5-6-12 Shinjuku Shinjuku-ku Tokyo 〒160-0022 Phone:+81(0)3 5919 1762 Fax:+81(0)3 5919 1702
Copyright(C);2011 Bio-Thera Clinic All rights Reserved.

6. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, RedmanBG.

Phase II trial of autologous tumor

vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal
cell cancer.

J Clin Oncol. 2003 Mar 1;21(5):884-90.

前立腺癌
1. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH,Vuk-Pavlovic S. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can
induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Prostate. 2004 Aug 1;60(3):197-204.
2. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM,Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with
HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine
trial involving patients with hormone-refractory metastatic disease.
Prostate. 1999 Jan 1;38(1):73-8.

MF Shinjuku Bldg. 5-6-12 Shinjuku Shinjuku-ku Tokyo 〒160-0022 Phone:+81(0)3 5919 1762 Fax:+81(0)3 5919 1702
Copyright(C);2011 Bio-Thera Clinic All rights Reserved.